

HEPATOLOGY

Faculty

Professor and Head	Y.K. Chawla	MD, DM, FAMS, FACG
Additional Professors	R.K. Dhiman	MD, DM, MNAMS, FACG
	Virendra Singh	MD, DM
Assistant Professor	Ajay Duseja	MD, DM, MNAMS, FACG

Prof. Y. Chawla chaired a session and gave a talk on “Current management strategies for Hepatitis C” at the Annual conference of Indian Association for Study of Liver (INASL) and International Liver Transplant Society (ILTS) meeting on 27-29 March 2009, New Delhi. He was invited to chair a session on “Infection and Liver Disease” at the 19th Asian Pacific Association for the Study of the Liver (APASL) Meeting at Hong Kong 13-16 Feb. 2009 and to deliver a talk at the Annual APICON-2009 on 29th January on “Hepatocellular Carcinoma – Recent developments in management”. He spoke on ‘HBV related HCC – molecular aspects’ at 4th Single Topic Conference on Viral Related Hepatocellular Carcinoma 5-7 Dec. 2008 at Bali, Indonesia. He was invited as a speaker for two talks on “Prevention and Management of Nosocomial infections in liver diseases; and “ccc-DNA clearance from infected hepatocyte should be the end point for treatment” at the Annual Asian Pacific Digestive Week and ISGCON at New Delhi on 14.9.08. He chaired a session on “Should CBD stone be cleared before or during Laparoscopic cholecystectomy” and was a panelist in the panel discussion on “Treatment of Chronic Hepatitis B” at the 46th Annual conference of Society of Gastrointestinal Endoscopy of India, ENDOCON 2008.

Dr R K Dhiman received prestigious Dr BC Roy Award (Category: Hari Om Ashram Research Award) for his outstanding contribution in liver diseases from the President of India. He was elected ‘Executive Member’ of prestigious international body – International Society on Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) for years 2008 to 2011. He presented the consensus “*Consensus development Meeting on Minimal Hepatic Encephalopathy*” at Annual Conference of Indian National

Association for Study of Liver (INASL) on March 27, 2009 at New Delhi. He participated at the 13th Symposium of International Society on Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) held at Padua, Italy on April 28 to May 1, 2008 in the capacity of Member, Advisory Board and presented his work entitled “Psychometric hepatic encephalopathy score, critical flicker frequency and P-300 event-related potentials for the diagnosis of minimal hepatic encephalopathy. He chaired a session on “Postgraduate Class” and gave a talk on “Management of Minimal Hepatic Encephalopathy” at the Annual Asian Pacific Digestive Week and ISGCON at New Delhi on 13th September 2008. He gave a talk on “Minimal Hepatic Encephalopathy” and was the panelist on a symposium “MHE: Unresolved issues” at the INASL and International Liver Transplant Society (ILTS) meeting on 27-29 March 2009, New Delhi.

Dr. Virendra Singh received ISG-Astra Oration for the year 2009; given by Indian Society of Gastroenterology at APDW Conference held at Delhi in Sept. 2008. He delivered a guest lecture on “Alcoholic Liver Disease: Management Strategies” at Abhigyan-2008 at Guwahati in April 2008. He also delivered guest lecture on “Differential diagnosis and management of ascites” at mid term INASL conference in August 2008 at GMCH, Chandigarh. He spoke on “HBsAg Positive HCW-Regulations and Management” at Mid-term monothematic conference of INASL at IMS, BHU, Varanasi in Dec. 2008.

Dr Ajay Duseja received the prestigious ISG- SR Naik Memorial Award for the year 2008 by the Indian Society of Gastroenterology for his best published work on NAFLD. He was guest speaker on ‘Imaging for Fat, Fibrosis and Inflammation in NAFLD - recent developments’ in the NAFLD symposium and ‘Treatment Efficacy in HBeAg-negative CHB’ in the symposium on ‘Optimizing Treatment Outcomes in CHB’ at the Annual conference of the INASL at New Delhi in March 2009. He was an invited speaker on ‘Milestone articles in Hepatology’ at the ‘Gastroenterology Young Masters - Training Program’ organized by ISG at New Delhi in Feb/March 2009. He was the National Coordinator and speaker on “NAFLD in India – Is it different’, NAFLD- Treatment’ and ‘NAFLD – Dos and Donts’ at the INASL-NAFLD task force meeting at Puri in February

2009. He spoke on ‘Role of FNAC in the diagnosis of HCC’ at the Grand rounds on liver tumors at Ganga Ram Hospital, New Delhi in January 2009. He was a guest speaker on ‘HBeAg negative CHB – Viral profile and natural history’ and clinical discussant for a CPC at INASL single theme conference on HBV at Varanasi in December 2008. He was a guest speaker on ‘PGI data on ACLF’ at INASL single theme conference on acute on chronic liver failure (ACLF) at Kolkata in December 2008. He chaired a session on ‘Landmark studies in GE and Hepatology from the Asia Pacific region’ at the Asia Pacific Digestive week (APDW) 2008 held at New Delhi in September 2008 and was a guest speaker on ‘Is cirrhosis reversible?’ at the Mid Term INASL conference at GMCH Chandigarh in August 2008.

Service

An outpatient liver clinic is conducted every Monday and Friday. A total of 9465 old and 2864 new patients were seen in liver clinic during 2008-2009.

During the year investigations performed included:

Name of Test/Procedure	2008-09	2007-2008	2006-2007
UGI Endoscopies	1409	1549	1125
Lower GI Endoscopies	101	110	75
ERCPS	226	240	192
Ultrasound	2811	2260	1996
Liver function tests	2695	3761	4383
Anti HCV	2721	4722	3130
HBsAg	3140	4650	3500
HBeAg/Anti HBe	1015	1732	522
Anti HEV (IgM)	430	-	-
Anti HBc (Igm)	187	-	-
Anti HBc (total)	100	-	-

These services were rendered to outpatients, patients attending special clinics, emergency and indoor patients.

Training

Residents of Internal Medicine rotated through the department for training imparted through regular sessions of clinical case discussions, topic discussions, hepato-radiology rounds, seminars, liver biopsy rounds and journal clubs. They were also trained to perform bedside procedures like liver biopsy, paracentesis, etc.

For the first time in the country, the department has started the DM programme in Hepatology and has taken five students in the year 2008-09. Senior residents undergoing training for DM (Gastroenterology) were posted in the department for two months. Five PhD students are undergoing training in the Department.

Research completed

ICMR

1. Serum pro and anti-angiogenic factors in hepatocellular carcinoma

Serum levels of VEGF, bFGF, angiogenin and endostatin were found to be high in cases of HCC when compared to cirrhosis, chronic hepatitis and healthy controls. These could be used as tumor markers in HCC but larger validation studies are needed.

Departmental

2. Plasma levels of PIVKA-II in Hepatocellular carcinoma

PIVKA-II levels were significantly high in HCC compared to cirrhosis, chronic hepatitis and healthy controls. This tumor marker correlated well with tumor size. This could also be used for the diagnosis of HCC.

3. Staging in cases of hepatocellular carcinoma

Patients with HCC were staged according to Okuda, TNM, BCLC, CLIP, modified CLIP, JIS, Tokyo score and GRETCH staging system. All these staging systems showed that most of our cases presented in very advanced stage. CLIP, Tokyo score and BCLC staging system showed a significant relationship to survival.

4. Role of bacterial overgrowth and delayed intestinal transit in minimal hepatic encephalopathy (MHE)

Ammonia derived from enteric bacterial flora is the key pathogenic mechanism in the development of MHE. Small intestinal bacterial overgrowth (SIBO) may play an important role. SIBO was the only significant factor found on multivariate analysis which influenced the presence of MHE in our patients with cirrhosis. Delayed oro-caecal transit time OCTT was the most important factor predicting SIBO ($P=0.001$) hence establishing the rationale behind treatment of these patients with prokinetics.

5. Prognostic Significance of Minimal Hepatic Encephalopathy detected by Psychometric Hepatic Encephalopathy Score in Patients with Cirrhosis of Liver

This study assessed (1) the usefulness of psychometric hepatic encephalopathy score (PHES) and critical flicker frequency (CFF) for the diagnosis of MHE and (2) prognostic significance of MHE. Multivariate analysis identified two variables as significant independent prognostic factors; associated with poor survival namely PHES ≤ -6 and Child-Turcotte-Pugh score ≥ 8 . PHES was an ideal assessment tool for the diagnosis of MHE in an outdoor setting.

6. A cross sectional study of prevalence of atherosclerosis and cardiovascular disease risk factors in patients with nonalcoholic fatty liver disease (NAFLD)

Prevalence of atherosclerosis and cardiovascular disease risk were assessed in twenty patients with NAFLD and 20 disease controls with chronic hepatitis B or chronic hepatitis C infection. Prevalence of atherosclerosis was studied by measuring carotid intima-media thickness (CIMT) on carotid ultrasound and by brachial artery doppler ultrasound before and after inflation of a pneumatic tourniquet. The risk of cardiac events at 10 years was estimated by Prospective Cardiovascular Munster study (PROCAM) score. Patients with NAFLD were found to have increased atherosclerosis and risk of cardiovascular disease, in comparison to controls.

Research in Progress

ICMR

1. A multicentric Randomized Controlled Clinical Trial of Adefovir, Adefovir + Lamivudine, and Combination of Adefovir and Glycyrrhizin in HBV related Decompensated Cirrhosis.
2. Alterations in gene expressions coding for key astrocytic and neuronal proteins in patients who have died from acute liver failure or chronic liver failure associated with hepatic encephalopathy.
3. Comparison of ablative therapies in hepatocellular carcinoma.
4. Role of cytokines and oxidative stress in patients with nonalcoholic steatohepatitis (NASH).

Pharmaceutical funded

5. An open label, response adaptive study of Telbivudine in adults with HBeAg positive compensated Chronic Hepatitis B
6. Supplementation with a probiotic preparation, VSL#3 as a support pharmaceutical therapy in cirrhotic patients for the treatment of minimal hepatic encephalopathy (MHE); A double-blind, randomized, placebo controlled study
7. Small Intestine bacterial overgrowth and role of probiotic, VSL#3 in patients with Nonalcoholic Fatty Liver Disease (NAFLD).

Departmental

8. Extrapyrarnidal signs in patients with cirrhosis of liver.
9. Role of psychometric hepatic encephalopathy score (PHES) and inhibitory control test (ICT) in the diagnosis of minimal hepatic encephalopathy.
10. Endoscopic management of postcholecystectomy biliary leaks.
11. Midodrine in refractory ascites in cirrhosis.
12. Noradrenaline and terlipressin in hepatorenal syndrome.
13. Toll like receptor gene expression and polymorphism in patients with nonalcoholic fatty liver disease.

Indexed publications

1. Dhiman RK, Chawla YK: Minimal hepatic encephalopathy. *Indian Journal of Gastroenterology* 2009; 28 :5-16.
2. Dhiman RK, Chawla Y: Hormone replacement therapy and gallstone disease: a real association. *Digestion* 2008; 77: 1-3.
3. Dhiman RK, Chawla YK: Minimal hepatic encephalopathy: Time to recognize and treat. *Tropical Gastroenterology* 2008; 29: 6-12.
4. Kiran M, Chawla YK, Kaur J: Glutathione-S-transferase and microsomal epoxide hydrolase polymorphism and viral-related hepatocellular carcinoma risk in India. *DNA Cell Biology* 2008; 27:687-94.
5. Chawla Y, Dhiman RK: Intrahepatic portal venopathy and related disorders of the liver. *Seminars in Liver Diseases*. 2008; 28:270-81.
6. Singh V, Dheerendra PC, Singh B, Nain CK, Chawla D, Sharma N, Bhalla A, Mahi SK: Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. *American Journal of Gastroenterology*. 2008; 103:1399-405.
7. Singh V, Bhalla A, Sharma N, Mahi SK, Lal A, Singh P: Pathophysiology of jaundice in amoebic liver abscess. *American Journal of Tropical Medicine Hygiene*. 2008 ;78:556-9
8. Singh V, Singh G, Verma GR et al: Contrast-free balloon-assisted unilateral plastic stenting in malignant hilar biliary obstruction: a new method. *Digestive Endoscopy* 2008; 20: 190–193.
9. Das K, Singh P, Chawla Y, Duseja A, Dhiman RK, Suri S: Magnetic resonance imaging of brain in patients with cirrhotic and non-cirrhotic portal hypertension. *Digestive Diseases and Sciences* 2008; 53:2793-8.
10. Das A, Duseja A, Liver pathology in nonalcoholic fatty liver disease. *Annals of National Academy of Medical Sciences* 2008; 44: 87-95.
11. Kalra N, Duseja A, Das A, Dhiman RK, Virmani V, Chawla Y, Singh P, Khandelwal N: Chemical shift magnetic resonance imaging is helpful in detecting

- hepatic steatosis but not fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). *Annals of Hepatology* 2009; 8: 21-5.
12. Chawla YK, Duseja A: Intrahepatic stones: is it a lifestyle disease? *Journal of Gastroenterology and Hepatology* 2008;23:998-9
 13. Duseja A, Dhiman RK, Chawla YK. Chronic hepatitis C and diabetes mellitus-- are they related? *Tropical Gastroenterology* 2008; 29:121-2.
 14. Gupta R, Chettri D, Sharma A, Duseja A, Dhiman RK, Chawla YK, Kalra N, Gupta A, Behera A. Pancreatic cysts causing biliary obstruction in von Hippel Lindau syndrome. *Journal of Pancreas*. 2008; 9:313-6.
 15. Kalra N, Vyas, Lal A, Duseja A, Nijhawan R, Khandelwal N. Biphasic multidetector CT of primary hepatic lymphoma in a patients with HIV infection. *Tropical Gastroenterology* 2008; 29: 169-71.
 16. Kalra N, Gulati A, Khandelwal N, Duseja A, Behra A, Joshi K. Pitfall in the diagnosis of biliary ascariasis. *J Clin Ultrasound*. 2009 Jan 28. (Epub ahead of print).

Chapters in Books

1. Chawla YK: Budd-chiari syndrome. In: *Tropical Hepatogastroenterology*. Tandon BN ed. Elsevier, Reed Elsevier India Private Limited. 2008; 413-422.
2. Dhiman RK, Chawla YK: Noncirrhotic portal fibrosis. In: *Tropical Hepatogastroenterology*. Tandon B.N. ed. Elsevier, Reed Elsevier India Private Limited. New Delhi 2008; 388-403.
3. Chawla YK, Duseja A. Extrahepatic portal venous obstruction. In: *Tropical Hepatogastroenterology*. Tandon BN ed. Elsevier, Reed Elsevier India Pvt. Limited, New Delhi, 2008; 404-412.
4. Dhiman RK. Investigations in hepatic disorders. In: *API Text Book of Medicine*; 8th Edn. SC Shah 2008; 670-672.
5. Singh V: Stem cell therapy. In: *The Liver Annual-2007- An INASL publication*.
6. Duseja A: . Bacterial cholangitis. In: *Gastrointestinal Tract Infections* Paragon International Publishers, New Delhi 2008; 416-24.

Research highlights

Part – I

PIVKA II is a useful tumor marker in patients with HCC. Its value increases with an increase in size of tumor. Small intestine overgrowth was found to be a significant factor which influenced the presence of minimal hepatic encephalopathy (MHE). Psychometric hepatic encephalopathy score (PHES) appears to be an ideal assessment tool for the diagnosis of MHE in an outdoor setting. Patients with non alcoholic fatty liver disease (NAFLD) have increased atherosclerosis and risk of cardiovascular disease.

Departmental highlights

Part II- (Highlights)

A 5-bedded Liver ICU and a 5 bedded High Dependency Unit (HDU) was started on 7th June 2008 for patients with acute liver failure, gastrointestinal bleeds, and hepatic encephalopathy. A DM programme was also started in Hepatology.

Dr R K Dhiman received prestigious Dr BC Roy Award for his outstanding contribution in liver diseases from the President of India. Dr. Virendra Singh received the ISG-Astra Oration for the year 2009; given by Indian Society of Gastroenterology. Dr Ajay Duseja received the prestigious ISG- SR Naik Memorial Award for the year 2008 by the Indian Society of Gastroenterology

HEPATOLOGY

Faculty

Professor and Head	Y.K. Chawla	MD, DM, FAMS, FACG
Additional Professors	R.K. Dhiman	MD, DM, MNAMS, FACG
	Virendra Singh	MD, DM
Assistant Professor	Ajay Duseja	MD, DM, MNAMS, FACG

Prof. Y. Chawla chaired a session and gave a talk on “Current management strategies for Hepatitis C” at the Annual conference of Indian Association for Study of Liver (INASL) and International Liver Transplant Society (ILTS) meeting on 27-29 March 2009, New Delhi. He was invited to chair a session on “Infection and Liver Disease” at the 19th Asian Pacific Association for the Study of the Liver (APASL) Meeting at Hong Kong 13-16 Feb. 2009 and to deliver a talk at the Annual APICON-2009 on 29th January on “Hepatocellular Carcinoma – Recent developments in management”. He spoke on ‘HBV related HCC – molecular aspects’ at 4th Single Topic Conference on Viral Related Hepatocellular Carcinoma 5-7 Dec. 2008 at Bali, Indonesia. He was invited as a speaker for two talks on “Prevention and Management of Nosocomial infections in liver diseases; and “ccc-DNA clearance from infected hepatocyte should be the end point for treatment” at the Annual Asian Pacific Digestive Week and ISGCON at New Delhi on 14.9.08. He chaired a session on “Should CBD stone be cleared before or during Laparoscopic cholecystectomy” and was a panelist in the panel discussion on “Treatment of Chronic Hepatitis B” at the 46th Annual conference of Society of Gastrointestinal Endoscopy of India, ENDOCON 2008.

Dr R K Dhiman received prestigious Dr BC Roy Award (Category: Hari Om Ashram Research Award) for his outstanding contribution in liver diseases from the President of India. He was elected ‘Executive Member’ of prestigious international body – International Society on Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) for years 2008 to 2011. He presented the consensus “*Consensus development Meeting on Minimal Hepatic Encephalopathy*” at Annual Conference of Indian National

Association for Study of Liver (INASL) on March 27, 2009 at New Delhi. He participated at the 13th Symposium of International Society on Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) held at Padua, Italy on April 28 to May 1, 2008 in the capacity of Member, Advisory Board and presented his work entitled “Psychometric hepatic encephalopathy score, critical flicker frequency and P-300 event-related potentials for the diagnosis of minimal hepatic encephalopathy. He chaired a session on “Postgraduate Class” and gave a talk on “Management of Minimal Hepatic Encephalopathy” at the Annual Asian Pacific Digestive Week and ISGCON at New Delhi on 13th September 2008. He gave a talk on “Minimal Hepatic Encephalopathy” and was the panelist on a symposium “MHE: Unresolved issues” at the INASL and International Liver Transplant Society (ILTS) meeting on 27-29 March 2009, New Delhi.

Dr. Virendra Singh received ISG-Astra Oration for the year 2009; given by Indian Society of Gastroenterology at APDW Conference held at Delhi in Sept. 2008. He delivered a guest lecture on “Alcoholic Liver Disease: Management Strategies” at Abhigyan-2008 at Guwahati in April 2008. He also delivered guest lecture on “Differential diagnosis and management of ascites” at mid term INASL conference in August 2008 at GMCH, Chandigarh. He spoke on “HBsAg Positive HCW-Regulations and Management” at Mid-term monothematic conference of INASL at IMS, BHU, Varanasi in Dec. 2008.

Dr Ajay Duseja received the prestigious ISG- SR Naik Memorial Award for the year 2008 by the Indian Society of Gastroenterology for his best published work on NAFLD. He was guest speaker on ‘Imaging for Fat, Fibrosis and Inflammation in NAFLD - recent developments’ in the NAFLD symposium and ‘Treatment Efficacy in HBeAg-negative CHB’ in the symposium on ‘Optimizing Treatment Outcomes in CHB’ at the Annual conference of the INASL at New Delhi in March 2009. He was an invited speaker on ‘Milestone articles in Hepatology’ at the ‘Gastroenterology Young Masters - Training Program’ organized by ISG at New Delhi in Feb/March 2009. He was the National Coordinator and speaker on “NAFLD in India – Is it different’, NAFLD- Treatment’ and ‘NAFLD – Dos and Donts’ at the INASL-NAFLD task force meeting at Puri in February

2009. He spoke on ‘Role of FNAC in the diagnosis of HCC’ at the Grand rounds on liver tumors at Ganga Ram Hospital, New Delhi in January 2009. He was a guest speaker on ‘HBeAg negative CHB – Viral profile and natural history’ and clinical discussant for a CPC at INASL single theme conference on HBV at Varanasi in December 2008. He was a guest speaker on ‘PGI data on ACLF’ at INASL single theme conference on acute on chronic liver failure (ACLF) at Kolkata in December 2008. He chaired a session on ‘Landmark studies in GE and Hepatology from the Asia Pacific region’ at the Asia Pacific Digestive week (APDW) 2008 held at New Delhi in September 2008 and was a guest speaker on ‘Is cirrhosis reversible?’ at the Mid Term INASL conference at GMCH Chandigarh in August 2008.

Service

An outpatient liver clinic is conducted every Monday and Friday. A total of 9465 old and 2864 new patients were seen in liver clinic during 2008-2009.

During the year investigations performed included:

Name of Test/Procedure	2008-09	2007-2008	2006-2007
UGI Endoscopies	1409	1549	1125
Lower GI Endoscopies	101	110	75
ERCPS	226	240	192
Ultrasound	2811	2260	1996
Liver function tests	2695	3761	4383
Anti HCV	2721	4722	3130
HBsAg	3140	4650	3500
HBeAg/Anti HBe	1015	1732	522
Anti HEV (IgM)	430	-	-
Anti HBc (Igm)	187	-	-
Anti HBc (total)	100	-	-

These services were rendered to outpatients, patients attending special clinics, emergency and indoor patients.

Training

Residents of Internal Medicine rotated through the department for training imparted through regular sessions of clinical case discussions, topic discussions, hepato-radiology rounds, seminars, liver biopsy rounds and journal clubs. They were also trained to perform bedside procedures like liver biopsy, paracentesis, etc.

For the first time in the country, the department has started the DM programme in Hepatology and has taken five students in the year 2008-09. Senior residents undergoing training for DM (Gastroenterology) were posted in the department for two months. Five PhD students are undergoing training in the Department.

Research completed

ICMR

3. Serum pro and anti-angiogenic factors in hepatocellular carcinoma

Serum levels of VEGF, bFGF, angiogenin and endostatin were found to be high in cases of HCC when compared to cirrhosis, chronic hepatitis and healthy controls. These could be used as tumor markers in HCC but larger validation studies are needed.

Departmental

4. Plasma levels of PIVKA-II in Hepatocellular carcinoma

PIVKA-II levels were significantly high in HCC compared to cirrhosis, chronic hepatitis and healthy controls. This tumor marker correlated well with tumor size. This could also be used for the diagnosis of HCC.

3. Staging in cases of hepatocellular carcinoma

Patients with HCC were staged according to Okuda, TNM, BCLC, CLIP, modified CLIP, JIS, Tokyo score and GRETCH staging system. All these staging systems showed that most of our cases presented in very advanced stage. CLIP, Tokyo score and BCLC staging system showed a significant relationship to survival.

7. Role of bacterial overgrowth and delayed intestinal transit in minimal hepatic encephalopathy (MHE)

Ammonia derived from enteric bacterial flora is the key pathogenic mechanism in the development of MHE. Small intestinal bacterial overgrowth (SIBO) may play an important role. SIBO was the only significant factor found on multivariate analysis which influenced the presence of MHE in our patients with cirrhosis. Delayed oro-caecal transit time OCTT was the most important factor predicting SIBO ($P=0.001$) hence establishing the rationale behind treatment of these patients with prokinetics.

8. Prognostic Significance of Minimal Hepatic Encephalopathy detected by Psychometric Hepatic Encephalopathy Score in Patients with Cirrhosis of Liver

This study assessed (1) the usefulness of psychometric hepatic encephalopathy score (PHES) and critical flicker frequency (CFF) for the diagnosis of MHE and (2) prognostic significance of MHE. Multivariate analysis identified two variables as significant independent prognostic factors; associated with poor survival namely PHES ≤ -6 and Child-Turcotte-Pugh score ≥ 8 . PHES was an ideal assessment tool for the diagnosis of MHE in an outdoor setting.

9. A cross sectional study of prevalence of atherosclerosis and cardiovascular disease risk factors in patients with nonalcoholic fatty liver disease (NAFLD)

Prevalence of atherosclerosis and cardiovascular disease risk were assessed in twenty patients with NAFLD and 20 disease controls with chronic hepatitis B or chronic hepatitis C infection. Prevalence of atherosclerosis was studied by measuring carotid intima-media thickness (CIMT) on carotid ultrasound and by brachial artery doppler ultrasound before and after inflation of a pneumatic tourniquet. The risk of cardiac events at 10 years was estimated by Prospective Cardiovascular Munster study (PROCAM) score. Patients with NAFLD were found to have increased atherosclerosis and risk of cardiovascular disease, in comparison to controls.

Research in Progress

ICMR

14. A multicentric Randomized Controlled Clinical Trial of Adefovir, Adefovir + Lamivudine, and Combination of Adefovir and Glycyrrhizin in HBV related Decompensated Cirrhosis.
15. Alterations in gene expressions coding for key astrocytic and neuronal proteins in patients who have died from acute liver failure or chronic liver failure associated with hepatic encephalopathy.
16. Comparison of ablative therapies in hepatocellular carcinoma.
17. Role of cytokines and oxidative stress in patients with nonalcoholic steatohepatitis (NASH).

Pharmaceutical funded

18. An open label, response adaptive study of Telbivudine in adults with HBeAg positive compensated Chronic Hepatitis B
19. Supplementation with a probiotic preparation, VSL#3 as a support pharmaceutical therapy in cirrhotic patients for the treatment of minimal hepatic encephalopathy (MHE); A double-blind, randomized, placebo controlled study
20. Small Intestine bacterial overgrowth and role of probiotic, VSL#3 in patients with Nonalcoholic Fatty Liver Disease (NAFLD).

Departmental

21. Extrapyrarnidal signs in patients with cirrhosis of liver.
22. Role of psychometric hepatic encephalopathy score (PHES) and inhibitory control test (ICT) in the diagnosis of minimal hepatic encephalopathy.
23. Endoscopic management of postcholecystectomy biliary leaks.
24. Midodrine in refractory ascites in cirrhosis.
25. Noradrenaline and terlipressin in hepatorenal syndrome.
26. Toll like receptor gene expression and polymorphism in patients with nonalcoholic fatty liver disease.

Indexed publications

17. Dhiman RK, Chawla YK: Minimal hepatic encephalopathy. *Indian Journal of Gastroenterology* 2009; 28 :5-16.
18. Dhiman RK, Chawla Y: Hormone replacement therapy and gallstone disease: a real association. *Digestion* 2008; 77: 1-3.
19. Dhiman RK, Chawla YK: Minimal hepatic encephalopathy: Time to recognize and treat. *Tropical Gastroenterology* 2008; 29: 6-12.
20. Kiran M, Chawla YK, Kaur J: Glutathione-S-transferase and microsomal epoxide hydrolase polymorphism and viral-related hepatocellular carcinoma risk in India. *DNA Cell Biology* 2008; 27:687-94.
21. Chawla Y, Dhiman RK: Intrahepatic portal venopathy and related disorders of the liver. *Seminars in Liver Diseases*. 2008; 28:270-81.
22. Singh V, Dheerendra PC, Singh B, Nain CK, Chawla D, Sharma N, Bhalla A, Mahi SK: Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. *American Journal of Gastroenterology*. 2008; 103:1399-405.
23. Singh V, Bhalla A, Sharma N, Mahi SK, Lal A, Singh P: Pathophysiology of jaundice in amoebic liver abscess. *American Journal of Tropical Medicine Hygiene*. 2008 ;78:556-9
24. Singh V, Singh G, Verma GR et al: Contrast-free balloon-assisted unilateral plastic stenting in malignant hilar biliary obstruction: a new method. *Digestive Endoscopy* 2008; 20: 190–193.
25. Das K, Singh P, Chawla Y, Duseja A, Dhiman RK, Suri S: Magnetic resonance imaging of brain in patients with cirrhotic and non-cirrhotic portal hypertension. *Digestive Diseases and Sciences* 2008; 53:2793-8.
26. Das A, Duseja A, Liver pathology in nonalcoholic fatty liver disease. *Annals of National Academy of Medical Sciences* 2008; 44: 87-95.
27. Kalra N, Duseja A, Das A, Dhiman RK, Virmani V, Chawla Y, Singh P, Khandelwal N: Chemical shift magnetic resonance imaging is helpful in detecting

- hepatic steatosis but not fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). *Annals of Hepatology* 2009; 8: 21-5.
28. Chawla YK, Duseja A: Intrahepatic stones: is it a lifestyle disease? *Journal of Gastroenterology and Hepatology* 2008;23:998-9
 29. Duseja A, Dhiman RK, Chawla YK. Chronic hepatitis C and diabetes mellitus-- are they related? *Tropical Gastroenterology* 2008; 29:121-2.
 30. Gupta R, Chettri D, Sharma A, Duseja A, Dhiman RK, Chawla YK, Kalra N, Gupta A, Behera A. Pancreatic cysts causing biliary obstruction in von Hippel Lindau syndrome. *Journal of Pancreas*. 2008; 9:313-6.
 31. Kalra N, Vyas, Lal A, Duseja A, Nijhawan R, Khandelwal N. Biphasic multidetector CT of primary hepatic lymphoma in a patients with HIV infection. *Tropical Gastroenterology* 2008; 29: 169-71.
 32. Kalra N, Gulati A, Khandelwal N, Duseja A, Behra A, Joshi K. Pitfall in the diagnosis of biliary ascariasis. *J Clin Ultrasound*. 2009 Jan 28. (Epub ahead of print).

Chapters in Books

7. Chawla YK: Budd-chiari syndrome. In: *Tropical Hepatogastroenterology*. Tandon BN ed. Elsevier, Reed Elsevier India Private Limited. 2008; 413-422.
8. Dhiman RK, Chawla YK: Noncirrhotic portal fibrosis. In: *Tropical Hepatogastroenterology*. Tandon B.N. ed. Elsevier, Reed Elsevier India Private Limited. New Delhi 2008; 388-403.
9. Chawla YK, Duseja A. Extrahepatic portal venous obstruction. In: *Tropical Hepatogastroenterology*. Tandon BN ed. Elsevier, Reed Elsevier India Pvt. Limited, New Delhi, 2008; 404-412.
10. Dhiman RK. Investigations in hepatic disorders. In: *API Text Book of Medicine*; 8th Edn. SC Shah 2008; 670-672.
11. Singh V: Stem cell therapy. In: *The Liver Annual-2007- An INASL publication*.
12. Duseja A: . Bacterial cholangitis. In: *Gastointestinal Tract Infections Paragon International Publishers, New Delhi* 2008; 416-24.

Research highlights

Part – I

PIVKA II is a useful tumor marker in patients with HCC. Its value increases with an increase in size of tumor. Small intestine overgrowth was found to be a significant factor which influenced the presence of minimal hepatic encephalopathy (MHE). Psychometric hepatic encephalopathy score (PHES) appears to be an ideal assessment tool for the diagnosis of MHE in an outdoor setting. Patients with non alcoholic fatty liver disease (NAFLD) have increased atherosclerosis and risk of cardiovascular disease.

Departmental highlights

Part II- (Highlights)

A 5-bedded Liver ICU and a 5 bedded High Dependency Unit (HDU) was started on 7th June 2008 for patients with acute liver failure, gastrointestinal bleeds, and hepatic encephalopathy. A DM programme was also started in Hepatology.

Dr R K Dhiman received prestigious Dr BC Roy Award for his outstanding contribution in liver diseases from the President of India. Dr. Virendra Singh received the ISG-Astra Oration for the year 2009; given by Indian Society of Gastroenterology. Dr Ajay Duseja received the prestigious ISG- SR Naik Memorial Award for the year 2008 by the Indian Society of Gastroenterology.
Society of Gastroenterology.